Business Wire

Milrem Robotics to Develop Several New Robotic Defence Systems

Del

Defence solutions provider Milrem Robotics is expanding the capabilities of their THeMIS unmanned ground vehicle to equip soldiers with several new robotic systems for defence applications.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912005974/en/

TITAN SENTRY is an exploration of manned/unmanned teaming where the cognitive burden on the warfight ...

TITAN SENTRY is an exploration of manned/unmanned teaming where the cognitive burden on the warfighter is vastly reduced through the fusion of sensor data and advanced battlespace management systems. (Photo: Business Wire)

One of the company’s aims is to enhance warfighters’ situational awareness. To that end several systems are in development. One of them – the TITAN SENTRY – will be exhibited this week during the Defence and Security Exhibition DSEI 2017.

Developed together with QinetiQ the TITAN SENTRY concept features the THeMIS unmanned ground vehicle, designed by Milrem Robotics and a suite of sensor systems integrated by QinetiQ. TITAN SENTRY is an exploration of manned/unmanned teaming where the cognitive burden on the warfighter is vastly reduced through the fusion of sensor data and advanced battlespace management systems. Intended to operate in high threat areas, it can identify and fix enemy locations whilst minimising the risk of casualties. This unit is on display at the QinetiQ stand S2-550.

Milrem Robotics has also started developing an unmanned system that combines the THeMIS with aerial drones. Working with Estonian UAV manufacturer Eli, a drone nest is being developed and with Threod Systems a tethered multirotor UAV integration project has begun.

These systems can be deployed in high risk situations or remote areas where oversight of a larger area is required without the need of a human operator to be present.

“Remotely controlled robotic systems that keep our soldiers in a safe distance are crucial to the next generation of battlefield effects that will give asymmetric advantage to the warfighter,” explained Kuldar Väärsi, the CEO of Milrem Robotics.

In support of Milrem Robotics’ integration projects, the company has just released the second part of the Digital Infantry Battlefield Solution (DIBS) study, focusing on the present and future use of robotic warfare systems. Put together by an academic study group for robotic warfare, DIBS2 gives an overview how military forces in USA, Ukraine, Poland and Russia are deploying unmanned ground systems but also focuses on ConOps and legal issues of using smart unmanned systems.

DIBS2 study can be found - http://bit.ly/ConOpDIBS

THeMIS + DroneNest - https://youtu.be/tF3D7FL3gtc

THeMIS + KX4 tethered UAV - https://youtu.be/NRWZcYqjbTM

Contact information

Milrem
Gert Hankewitz
Export Director
gert.hankewitz@milrem.om
+37256644416

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 08:43Pressemelding

LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova

Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 08:29Pressemelding

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em

Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 08:00Pressemelding

Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio

Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 08:00Pressemelding

(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p

Record Attendance at Japan Content Showcase 2017!20.11.2017 03:00Pressemelding

Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti

Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01Pressemelding

Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom